This is especially important given the known resistance to immune checkpoint blockade in EGFRMT lung cancers relative to that in NSCLC patients without EGFR mutations (49–52) and the possibility that targeting MERTK could overcome this immune resistance. This evidence concerns the gene MERTK and non-small cell lung carcinoma.